This material is an English translation of the press release announced on Dec. 5, 2023 in Japanese, and the Japanese release is given priority about the content and the interpretation.

Dec. 5, 2023

Notice Regarding Status of Acquisition of Treasury Shares

(Acquisition of treasury shares in accordance with the provisions of the Articles of Incorporation pursuant to Article 165, paragraph 2 of the Companies Act)

Hisamitsu Pharmaceutical Co., Inc. (Head office: Tosu City, Saga Prefecture; President and CEO: NAKATOMI, Kazuhide) hereby announces the status (in progress) of acquisition of treasury shares in accordance with Article 156 of the Companies Act as applied pursuant to Article 165, paragraph 3 of the same Act, as announced on July 13, 2023, as follows.

1. Type of shares acquired　Common shares of the Company
2. Total number of shares acquired　312,500 shares
3. Total amount of shares acquired　1,457,924,500 yen
4. Period for acquisition　November 1, 2023 to November 30, 2023 (based on contract)
5. Method of acquisition　Market purchase on the Tokyo Stock Exchange

(Reference)

1. Resolutions of the board of directors meeting held on July 13, 2023
   (1) Type of shares to be acquired: Common shares of the Company
   (2) Total number of shares that may be acquired: 2 million shares (maximum)
   (Percentage of total number of shares outstanding (excluding treasury shares): 2.57%)
   (3) Total amount of shares acquired: 10 billion yen (maximum)
   (4) Period for acquisition: July 14, 2023 to February 29, 2024
   (5) Method of acquisition: Market purchase on the Tokyo Stock Exchange

2. Cumulative total of treasury shares acquired based on the above resolutions of the board of directors meeting (as of November 30, 2023)
   (1) Total number of shares acquired　1,633,400 shares
   (2) Total amount of shares acquired　8,140,321,900 yen